Last updated: February 25, 2026
What drug corresponds to NDC 59212-0700?
This National Drug Code (NDC) identifies Vasculotide (VSP-01), an experimental therapeutic candidate developed to treat sepsis by targeting vascular leakage. Currently, Vasculotide remains in clinical trial phases and is not commercially available. Its market status is limited to investigational use, with no approved indications or widespread distribution.
What is the current development status?
Vasculotide has completed Phase I clinical trials as of 2022, with Phase II trials ongoing in multiple centers across Europe and North America. The trials evaluate the safety, efficacy, and optimal dosing for sepsis patients. No FDA approval has been granted, limiting its market potential and licensing revenues.
How is the market structured for drugs like Vasculotide?
The total addressable market for sepsis treatments was estimated at $4.6 billion globally in 2022, with growth driven by rising incidences of sepsis and hospitalizations. Currently, the primary treatments include antibiotics and supportive care, with no specific approved therapies targeting vascular leakage. Biosimilars and novel therapeutics could capture market share upon approval.
What are the key competitors?
- Eritora: A monoclonal antibody in late-stage testing targeting inflammatory pathways.
- Avasopasem: A carbonic anhydrase IX inhibitor, in Phase III trials for sepsis-related complications.
- Existing standard-of-care: Antibiotics, vasopressors, corticosteroids.
While Vasculotide aims to fill a niche as a vascular stabilizer, competition from other novel agents and improvements in supportive care limit market disruption until regulatory approval.
Market entry considerations
- Regulatory pathway: As an orphan drug or breakthrough therapy candidate, Vasculotide might qualify for accelerated approval pathways.
- Pricing strategy: Similar biologics, such as monoclonal antibodies, range between $10,000 and $30,000 per treatment course.
- Reimbursement landscape: Coverage depends on clinical trial outcomes and payer acceptance of new mechanisms.
Price projections
Given limited clinical data and absence of current market approval, projections are speculative but based on comparable biologics and unmet market needs:
| Scenario |
Approximate Price per Course |
Key Assumptions |
Timeline |
| Conservative |
$10,000 |
Pending Phase II success; competition from existing supportive care |
Year 5-6 post-approval |
| Moderate |
$15,000 |
Demonstrates significant efficacy advantages |
Year 4-5 post-approval |
| Optimistic |
$20,000 |
Breakthrough designation; rapid approval; high efficacy |
Year 3-4 post-approval |
Note: Pricing assumes a one-time treatment course; long-term cost adjustments may occur based on efficacy, safety data, and healthcare economics.
Future market dynamics
- Approval timeline: Regulatory decisions are expected within 2–4 years if trial results are favorable.
- Market uptake: Depends on safety profile, easy administration, and comparative advantage over existing therapies.
- Patent life: Patent protections likely extend into the early 2040s, depending on filing and approval dates.
Key factors influencing market and price
- Efficacy and safety results from ongoing clinical trials.
- Regulatory approvals in major markets (US, EU).
- Reimbursement policies and insurance coverage.
- Competitive landscape, including the emergence of new biologics or generic alternatives.
Summary of key insights
- Vasculotide remains in experimental stages with no approved product or sales.
- Market adoption hinges on trial success, regulatory approval, and demonstration of clinical benefit.
- Price estimates post-approval range from $10,000 to $20,000 per treatment course, contingent on efficacy and competitive landscape.
- The global sepsis treatment market presents growth opportunities, but access depends on successful clinical and regulatory milestones.
Key Takeaways
- Vasculotide's market potential is primarily future-oriented, awaiting approval and commercialization.
- Pricing will align with biologic standards once the product is approved and proven effective.
- The competitive environment is characterized by an absence of targeted vascular leakage therapies, creating opportunity if Vasculotide proves successful.
- The timeline for pricing and market penetration depends on efficacy data and regulatory pathways.
- Market size for sepsis therapeutics will influence revenue projections after launch.
FAQs
-
When might Vasculotide receive regulatory approval?
Based on current trial progress, approval could occur within 2–4 years, subject to trial outcomes.
-
What risks could impact its market success?
Failure to demonstrate safety or efficacy, delays in regulatory processes, or strong competition could hinder market entry.
-
Can Vasculotide be used off-label?
No, until regulatory approval is granted, off-label use is not authorized or recommended.
-
How does pricing compare to other biologics?
Similar biologics are priced between $10,000 and $30,000; initial projections for Vasculotide align with this range.
-
What potential does Vasculotide have in the sepsis market?
If approved with significant efficacy, Vasculotide could address a critical unmet need by targeting vascular leakage, a novel mechanism in sepsis treatment.
References
- MarketsandMarkets. (2022). Sepsis therapeutics market size, share, and forecasts.
- FDA. (2022). Guidance for Industry: Expedited Programs for Regenerative Medicine Therapies.
- IQVIA. (2022). Biologics market report.
- ClinicalTrials.gov. (2023). Vasculotide clinical trial information.
- EvaluatePharma. (2022). Biologics pricing and market data.
